NEW YORK (GenomeWeb News) — Millipore today said that it will market and distribute JPT Peptide Technologies’ line of enzyme profiling products and services targeting enzymes such as kinases, phosphatases, and proteases.
JPT is a wholly owned subsidiary of Berlin-based Jerini. The non-exclusive deal is worldwide.
JPT's products “strongly complement our existing portfolio of cell signaling reagents and services,” Rick Ryan, vice president of the drug discovery business unit for the bioscience division of Millipore, said in a statement.
Financial terms of the deal were not disclosed.